Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is recommended as an option for restricted use within NHS Wales. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is licensed for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is restricted for use to patients who are either unsuitable for or unable to tolerate dolutegravir/abacavir/lamivudine (Triumeq®). Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) | ||
| Formulation | 50 mg, 200 mg, 25 mg film-coated tablet | ||
| Reference number | 3414 | ||
| Indication | Treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. |
||
| Company | Gilead Sciences Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 1918 | ||
| NMG meeting date | 10/10/2018 | ||
| AWMSG meeting date | 14/11/2018 | ||
| Date of issue | 03/12/2018 | ||
| Date of last review | April 2022 | ||
| Commercial arrangement | WPAS | ||
| Further information This appraisal recommendation was reviewed in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations. |
|||